The Technical Analyst
Codexis Inc [CDXS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Codexis Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.40% $2.90
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 203.88 mill |
| EPS: | -1.120 |
| P/E: | -2.59 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 70.30 mill |
| Avg Daily Volume: | 0.583 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.59 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.44x |
| Company: PE -2.59 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.63 - 3.17 ( +/- 9.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-01 | Ryali Sriram | Buy | 314 125 | Stock Option (Right to Buy) |
| 2024-01-01 | Ryali Sriram | Buy | 52 350 | Common Stock |
| 2024-01-01 | Norrett Kevin | Buy | 314 125 | Stock Option (Right to Buy) |
| 2024-01-01 | Norrett Kevin | Buy | 52 350 | Common Stock |
| 2024-01-01 | Fitzgerald Margaret Nell | Buy | 314 125 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 78.99 |
| Last 93 transactions |
| Buy: 6 649 590 | Sell: 1 047 461 |
Forecast:
16:00 - $2.89
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.89
Forecast 2: 16:00 - $2.89
Forecast 3: 16:00 - $2.89
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.90 (1.40% ) |
| Volume | 0.168 mill |
| Avg. Vol. | 0.583 mill |
| % of Avg. Vol | 28.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CDXS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.92 | N/A | Active |
|---|
CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Latest Press Releases
2024-04-18 16:05:00 - Press Release
Codexis To Report First Quarter 2024 Financial Results On May 2
Redwood city, calif., april 18, 2024 (globe newswire) -- codexis, inc. (nasdaq: cdxs), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on thursday, may 2, 2024, following the close of market. codexis management will host a conference call and webcast at 4:30 pm eastern time to discuss the company's financial results and provide a business update.
2024-04-11 07:05:00 - Press Release
Codexis Appoints Carole Cobb, Mba, To Strategic Advisory Board
Cobb adds rna industry operations and commercial expertise to support continued development of eco synthesis™ manufacturing platform cobb adds rna industry operations and commercial expertise to support continued development of eco synthesis™ manufacturing platform
2024-02-28 16:05:00 - Press Release
Codexis Reports Fourth Quarter And Fiscal Year 2023 Financial Results
Anticipate 2024 product revenue growth of at least 10% vs. 2023 excluding enzyme sales related to paxlovid™ recently announced debt financing reinforces strong financial position with projected runway through expected positive cash-flow around end of 2026 2024 to focus on securing early access customers for eco synthesis™ manufacturing platform, launch of double-stranded rna ligase and return to growth for pharmaceutical manufacturing redwood city, calif.
2024-02-26 16:05:00 - Press Release
Codexis Enters Exclusive Licensing Agreement For Newly Engineered Double-stranded Dna Ligase With Roche
Redwood city, calif., feb. 26, 2024 (globe newswire) -- codexis, inc. (nasdaq: cdxs), a leading enzyme engineering company, today announced it has entered into an agreement with roche for an exclusive, global license for the company's newly engineered double-stranded dna (dsdna) ligase for next-generation sequencing (ngs) library preparation and the company's evot4™ dna ligase. under the terms of the deal, codexis will receive upfront and technical milestone payments. this deal supersedes the prior exclusive license on the evot4™ dna ligase.
2024-02-26 08:05:00 - Press Release
Codexis To Participate In Td Cowen 44th Annual Health Care Conference
Redwood city, calif., feb. 26, 2024 (globe newswire) -- codexis, inc. (nasdaq: cdxs), a leading enzyme engineering company, today announced the company will attend the td cowen 44th annual health care conference, being held march 4-6, 2024, in boston, massachusetts.
Latest News
2024-04-18 16:05:00 - GlobeNewsWire
Codexis to Report First Quarter 2024 Financial Results on May 2
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
2024-02-28 22:39:05 - Seeking Alpha
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
2024-02-28 19:51:03 - Zacks Investment Research
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.
2024-02-16 08:56:12 - Zacks Investment Research
WIX Set to Report Q4 Earnings: Here's What You Should Know
WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.
2024-02-14 16:05:00 - GlobeNewsWire
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
2023-11-29 14:46:40 - InvestorPlace
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Synthetic biology refers to using engineered organisms to produce products for multiple industries. Specifically, the pharmaceutical, biotechnology, and agriculture sectors are set to benefit most from synthetic biology.
2023-11-02 21:32:19 - Seeking Alpha
Codexis, Inc. (CDXS) Q3 2023 Earnings Call Transcript
2023-10-27 15:35:00 - GlobeNewsWire
Codexis to Present Update on ECO Synthesis™ Platform at TIDES Europe
REDWOOD CITY, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced a presentation highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES Europe annual meeting taking place in Amsterdam, Netherlands and virtually October 30-November 1, 2023.
2023-10-19 16:05:00 - GlobeNewsWire
Codexis to Report Third Quarter 2023 Financial Results on November 2
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
2023-10-05 14:11:41 - Seeking Alpha
Checking Out Codexis
Codexis, Inc. is undergoing a significant restructuring to reduce costs, refocus its developmental efforts and streamline its organization. The company's ECO platform to provide enzymes for RNA therapeutics shows some potential, but the company's cash burn rate remains concerning. Insider purchases and consolidation of operations may indicate a turnaround, but previous insider selling this year raises concerns about management's commitment.